The iron chelator deferasirox protects mice from mucormycosis through iron starvation
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Mucormycosis causes mortality in at least 50% of cases despite current first-line therapies. Clinical and animal data indicate that the presence of elevated available serum iron predisposes the host to mucormycosis. Here we demonstrate that deferasirox, an iron chelator recently approved for use in humans by the US FDA, is a highly effective treatment for mucormycosis. Deferasirox effectively chelated iron from Rhizopus oryzae and demonstrated cidal activity in vitro against 28 of 29 clinical isolates of Mucorales at concentrations well below clinically achievable serum levels. When administered to diabetic ketoacidotic or neutropenic mice with mucormycosis, deferasirox significantly improved survival and decreased tissue fungal burden, with an efficacy similar to that of liposomal amphotericin B. Deferasirox treatment also enhanced the host inflammatory response to mucormycosis. Most importantly, deferasirox synergistically improved survival and reduced tissue fungal burden when combined with liposomal amphotericin B. These data support clinical investigation of adjunctive deferasirox therapy to improve the poor outcomes of mucormycosis with current therapy. As iron availability is integral to the pathogenesis of other infections (e.g., tuberculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This pathway appears to be partly responsible for the beneficial clinical effects of iron chelators observed in several experimental infection systems (Mencacci et al., 1997; Fritsche et al., 2001; Ibrahim et al., 2007; Bellmann-Weiler et al., 2013; Nairz et al., 2013).”
From Iron at the interface of immunity and infection (2014) · cites this paper as Ibrahim et al., 2007
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, the Fe chelator desferasirox, which cannot be used by molds to acquire Fe, improves survival of infected mice, limiting Fe availability to the pathogen while enhancing host resistance mechanisms [238].”
From The Iron age of host–microbe interactions (2015) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Hentze, M. W., Muckenthaler, M. U., & Andrews, N. C. (2004) · Cell · doi:10.1016/s0092-8674(04)00343-5 · Cited by 1,736
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Self-citationEpidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Schaible, U. E., & Kaufmann, S. H. E. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro1046 · Cited by 945
Cappellini, M. D. (2006) · Blood · doi:10.1182/blood-2005-08-3430 · Cited by 717 · cited 2×
“Furthermore, it is known that deferasirox chelation is specific for iron and that other trace metals and cations are not affected by the drug (27, 28).”
Zygomycosis in the 1990s in a Tertiary-Care Cancer Center
Kontoyiannis, D. P., Wessel, V. C., Bodey, G. P., & Rolston, K. V. I. (2000) · Clinical Infectious Diseases · doi:10.1086/313803 · Cited by 521
Artis, W. M., Fountain, J. A., Delcher, H. K., & Jones, H. E. (1982) · Diabetes · doi:10.2337/diabetes.31.12.1109 · Cited by 369 · cited 2×
“Alternatively, the enhanced efficacy of deferasirox in the diabetic ketoacidotic mouse model might reflect the ability of this iron chelator to efficiently chelate serum iron previously freed by proton-mediated dissociation from iron-sequestering proteins (2, 16, 17).”
Boelaert, J. R., de Locht, M., Van Cutsem, J., Kerrels, V, Cantinieaux, B., Verdonck, A., Van Landuyt, H. W., & Schneider, Y. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116419 · Cited by 340 · cited 2×
“The potential therapeutic role of iron chelation therapy for mucormycosis was initially obscured by the paradoxically increased risk of developing mucormycosis during treatment with deferox-amine (18).”
Research works printed but not linked: 4
- Ganz, 2006, Curr. Top. Microbiol. Immunol., 306, 183
- Artis, 1982, Diabetes., 31, 1109, 10.2337/diacare.31.12.1109 · doi:10.2337/diacare.31.12.1109 · Paper page
- Fu, 2004, FEMS Microbiol. Lett., 235, 169
- Ibrahim, A.S., et al. 2000. Comparison of amphotericin B and amphotericin B lipid complex in the treatment of murine-induced zygomycosis. In 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17–20. Toronto, Ontario, Canada. American Society of Microbiology. Abstract 1681.
Cited by
Items 301–327 of 327
Schwartze, V. U., Winter, S., Shelest, E., Marcet‐Houben, M., Horn, F., Wehner, S., Linde, J., Valiante, V., Sammeth, M., Riege, K., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006491
“In addition, mucoralean fungi are also able to utilize deferoxamine, a bacterial siderophore which is used as an iron-chelator in human therapy [66,67].”
BackgroundFaculty Opinions recommendation of Molecular mechanisms of mucormycosis-The bitter and the sweet.
Lortholary, O. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727876937.793550314
Perfect, J. R. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-24
Patterson, T. F. (2008) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1124037.581152
Mucormycosis and Its Co-Relation with Raised Ferritin Levels
Chahande, S., Kashid, G. M., Gaikwad, A., Futane, A., Purohit, S. A., Waghmare, S. K., & Palve, H. (2022) · VIMS Health Science Journal · doi:10.46858/vimshsj.9202
Zuo, M., Sun, Y., & Zhu, L. (2022) · doi:10.22541/au.166185902.29942078/v1
Prevention and Treatment of COVID-19-Associated Mucormycosis
Grafmiller, K. T., & Lee, J. T. (2023) · Current Treatment Options in Allergy · doi:10.1007/s40521-023-00339-4
Factors Impacting Outcome and Prognosis of Invasive Fungal Sinusitis: How Vital is Iron Metabolism?
Verma, P., Sikka, K., Verma, H., Kumar, R., Thakar, A., Soneja, M., & Singh, V. (2024) · Indian Journal of Otolaryngology and Head & Neck Surgery · doi:10.1007/s12070-024-04643-6
“Ibrahim et al. [18] reported the protective effects of the iron-chelating agent deferasirox against mucormycosis in mice.”
Comprehensive Review on COVID-19 associated Mucormycosis: Diagnosis, Types and Treatment
Munot, N. M., Raut, M. T., Kandekar, U., Rai, N., & Gaikwad, P. V. (2024) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3227
Joshi, S. V., & Havaldar, R. R. (2024) · Indian Journal of Otolaryngology and Head & Neck Surgery · doi:10.1007/s12070-024-04812-7
“For the same reason iron supplementation may also be avoided [15–17].”
Mucormycosis: Current Perspectives on Treatment, Diagnosis, and Advancements
Biswas, T., Sharma, V., & Mittal, R. K. (2024) · Coronaviruses · doi:10.2174/0126667975333545241011060632
Non-Aspergillus Pulmonary Mold Infections
Muthu, V., & Chakrabarti, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-76524-7_25
Patil, A., Desai, T., & Tirgar, P. (2025) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2025.170207
Mucormycosis and Entomophthoramycosis
Wattier, R. L., & Steinbach, W. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00223-5
Novel Therapeutic Approaches to Control Fungal Biofilms
Guisso, L. P., Ribeiro, N. P., Carmona, W. R., Roseno, A. C. B., Pessan, J. P., & Monteiro, D. R. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_11
Singh, R., Kaur, J., Kaur, P., & Sharma, A. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108577
Al-Rhman, R. M. A., Mahmood, M. S., & Turky, H. A. (2025) · Journal of Medical Genetics and Clinical Biology · doi:10.61796/jmgcb.v2i10.1421
Management of Aspergillosis, Zygomycosis, and Other Clinically Relevant Mold Infections
Leventakos, K., & Kontoyiannis, D. P. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-644-3_25
Taxonomy and phylogeny of clinically important mucoralean fungi
Duarte, E. A. Á. (2011) · Rovira & Virgili repository
Infeções por zigomicetos da ordem mucorales : patogénese, epidemiologia e terapêutica
Gina, A. G. S. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Mucormycosis in post– COVID-19 patients: Emerging threat and clinical challenges in India
Durai, S. (2025) · International Journal of Zoology and Applied Biosciences · doi:10.55126/ijzab.2025.v10.i06.sp007
Mapping Mucormycosis Research: A 25-Year Bibliometric Analysis of Medical Literature
KAYTA, S. B. G., Alkan, S., & Evlice, O. (2026) · Infectious Diseases and Clinical Microbiology · doi:10.36519/idcm.2026.753
Human mucormycosis; current perspectives
Thalagala, A. R. P., Gunathilaka, S. S., Bandara, M. W., Adhikari, A. C., Madhuwantha, K. C., & Jayaweera, J. A. A. S. (2026) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000457
Iron and the lung: emerging roles of iron metabolism in pulmonary disease pathogenesis and therapy
Galaris, A., Toumpanakis, D., Galaris, D., Vassilakopoulos, T., & Pantopoulos, K. (2026) · European Respiratory Review · doi:10.1183/16000617.0160-2026
“Deferasirox has also shown protective effects in models of pulmonary infection by limiting iron availability to pathogens [152, 153].”
A Brief Review About Mucormycosis (Black Fungus)
Priya Pandey, D. G., Garg, D., Bhardwaj, A., Thakur, S., Sonal, K., & Kumar, N. (2023) · Journal of Pharmaceutical Negative Results · doi:10.47750/pnr.2023.14.s02.298
Dogra, S., Arora, A., Aggarwal, A., Passi, G., Sharma, A., Singh, G., & Barnwal, R. P. (2022) · doi:10.3389/fmicb.2021.794176.s001
Metadata
- Authors
- Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J.
- Affiliations
- University of California, Los Angeles (US)
- Charles River Laboratories (United States) (US)
- National Center for Agricultural Utilization Research (US)
- Corresponding author
- Ibrahim, Ashraf S.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2007-09-04
- Volume
- 117
- Issue
- 9
- Pages
- 2649-2657
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1957543
- OpenAlex
- W2113977119
- Cited by
- 308
- References
- 43
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 13 · 2023: 16 · 2022: 17 · 2021: 21 · 2020: 15 · 2019: 12 · 2018: 12 · 2017: 12 · 2016: 12 · 2015: 15 · 2014: 20 · 2013: 23 · 2012: 25
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Gilead Sciences
- National Institute of Allergy and Infectious Diseases (R01 AI63503-01A2, R01AI019990, K08AI060641, AI-063382, R01-AI19990, R21AI064716, R01AI063382, R01AI063503)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- mucormycosis, deferasirox, iron chelation, iron starvation, Mucorales, Rhizopus oryzae, liposomal amphotericin B, antifungal therapy, diabetic ketoacidosis, neutropenia, host inflammatory response, serum iron, adjunctive therapy
- MeSH terms
- Deferasirox, Amphotericin B, Animals, Benzoates, Diabetes Mellitus, Drug Therapy, Combination, Iron, Iron Chelating Agents, Liposomes, Male, Mice, Inbred BALB C, Mucorales, Mucormycosis, Triazoles, Survival Rate, Th1 Cells, Th2 Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.